Journal
CELL AND BIOSCIENCE
Volume 10, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13578-020-00391-6
Keywords
Telomere; Telomere maintenance mechanism; Alternative lengthening of telomeres (ALT); APBs; Phase separation; ALT telomeric DNA synthesis; RAD52; BLM; FANCM; Clinical therapy
Categories
Funding
- MGH Cancer Center Excellence Award
Ask authors/readers for more resources
To escape replicative senescence, cancer cells have to overcome telomere attrition during DNA replication. Most of cancers rely on telomerase to extend and maintain telomeres, but 4-11% of cancers use a homologous recombination-based pathway called alternative lengthening of telomeres (ALT). ALT is prevalent in cancers from the mesenchymal origin and usually associates with poor clinical outcome. Given its critical role in protecting telomeres and genomic integrity in tumor cells, ALT is an Achilles heel of tumors and an attractive target for cancer therapy. Here, we review the recent progress in the mechanistic studies of ALT, and discuss the emerging therapeutic strategies to target ALT-positive cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available